Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Leerink Partners analyst Andrew Berens maintained a Buy rating on Immunome (IMNM – Research Report) on January 13. The company’s shares closed ...

Research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Vir Biotechnology in a ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price objective raised by Leerink Partners from $18.00 to $20.00 in a research report issued to clients and investors on Monday ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (WBAG:ALGN) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (LSE:0HCK) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...